Des-1357

Preclinical

DD. E. Shaw Research, LLC

Des-1357 is one of 3 therapeutic programs targeting Metastatic Colorectal Cancer (CRC). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Metastatic Colorectal Cancer (CRC)Not yet recruiting

Metastatic Colorectal Cancer (CRC)Preclinical

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Metastatic Colorectal Cancer (CRC)

#DrugCompanyPhaseTrials

Elunate

Takeda

Phase 2

1 2

Erbitux

IImclone

Preclinical

1 3

Des-1357

DD. E. Shaw Research, LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalNot yet recruiting

Metastatic Colorectal Cancer (CRC)

NCT07807800

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer (CRC)1 trial

A Phase 1/2 Adaptive Study of DES-1357 in Participants With Deficient Mismatch Repair (dMMR) and/or Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC)

Not yet recruiting·DD. E. Shaw Research, LLC·Preclinical·NCT07807800·88 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Des-1357. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Des-1357. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — D. E. Shaw Research, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: DD. E. Shaw Research, LLC

Des-1357

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Metastatic Colorectal Cancer (CRC)1 trial

References

Drug Info

Quick Facts

Related News